Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 1684091 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 1852583 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2082558 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2088098 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2114738 | Peak area | PAK | TNF-alpha |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2160955 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2213163 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2365396 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2383618 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2421187 | Peak area | HAHA | IFN-G |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2479594 | Peak area | HAHA | TNF-alpha |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2497470 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2729790 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 2875890 | Peak area | HAHA | IL-17A |
Reversed phase NEGATIVE ION MODE | LEUCINE (CAS# 328-39-2); (M-H)- | 3464109 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 12900000 | Peak area | HAHA | TNF-alpha |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 13100000 | Peak area | PAK | TNF-alpha |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 13300000 | Peak area | PAK | Untreated |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 13400000 | Peak area | HAHA | IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 13500000 | Peak area | HAHA | IFN-G |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 13900000 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14200000 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14300000 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14400000 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14500000 | Peak area | BS4 | IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14700000 | Peak area | BS4 | Untreated |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 14900000 | Peak area | PAK | IFN-G |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 15900000 | Peak area | BS4 | TNF-alpha |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 16500000 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | LEUCINE (CAS# 328-39-2); (M+H)+ | 16700000 | Peak area | BS4 | IFN-G |